$12.67
-0.24-1.86%
At close: -
$12.67
0.000.00%
After Hours: Jan 31, 4:00 PM EDT
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
The most recent guidance for Myriad Genetics (MYGN) was reported on January 15, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $0.07 to $0.11, compared to the estimated EPS of $0.09. Additionally, Myriad Genetics forecasted revenue between $0.84B and $0.86B for the quarter.
Browse guidance and forecast on all stocks.